Published on
February 22, 2022

Lobe Sciences Ltd Invites You to Join Us at the Q1 Virtual Investor Summit

Vancouver, British Columbia--(Newsfile Corp. - February 22, 2022) - Lobe Sciences Ltd (CSE: LOBE) (OTCQB: LOBEF) today announced that Philip Young CEO will be attending the Q1 Virtual Investor Summit. During this presentation Lobe’s CEO Philip Young will provide highlights of the Company’s plans for for advancing into human clinical trials in 2022. The presentation will be webcast and an archived recording will be made available in the investors’ section of the Lobe Sciences website.

Event: Q1 Investor Summit

Date: March 8-9th, 2022

Presentation: March 9th at 10:15 AM ET


About Lobe Sciences Ltd

Lobe Sciences is a life sciences company focused on developing sub-psychedelic doses of psychedelic medicines targeting the 5-HT2A receptor. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds in conjunction with NAC (N-acetyl cysteine) to improve brain and mental health and wellness.

For further information:

Lobe Sciences Ltd
Philip Young

About the Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. Contact: